MSD Animal Health Grants Federation of Veterinarians of Europe (FVE) $200,000 for Awards for 68 Veterinary Students

Rahway, NJ, January 24, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) is proud to announce that 68 veterinary students out of 41 faculties across 26 European countries have been selected for the Veterinary Student Scholarship Program (FVE) 2023. For the year 2023, MSD Animal Health granted to the Federation of Veterinarians of Europe $200,000 USD to be awarded to 68 veterinary students in the third, fourth, and fifth year of study. That is an average of approximately $3,000 USD per student.

The Review Committee selected 68 students out of 212 applications. The students selected come from the following countries: Austria, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Turkey, Ukraine, and the United Kingdom.

Among the 68 successful students, eight grants go to students from Spain, seven to students of faculties in Italy, Romania, and the UK and five to students from Poland. They are followed by France with four and Estonia, Greece, Ireland with three students each, Bulgaria, Portugal, Slovakia and Turkey with two each and other grants are distributed among the remaining countries.

“Investing in the education of European veterinary students, is investing in the future of our profession” said FVE president Sigfried Moder. “We are grateful that through these scholarships FVE can play a role in ensuring we have future veterinarians with the skills and training necessary to treat our animals, safeguard our food and protect public”.

“MSD Animal Health is delighted to continue this wonderful tradition and valued partnership to support these deserving students who are the future of our veterinary profession,” said Rob Kelly, senior vice president and head of MSD Animal Health, EURAM. “Veterinarians are the foundation of animal health – from helping discover new and innovative ways to managing and preventing diseases to diagnosing and treating the animals in their care.”

The partnership between FVE and MSD Animal Health has provided scholarships for over 364 veterinary students in the last eight years, many of whom will surely become young leaders in the veterinary field.

About FVE

The Federation of Veterinarians of Europe (FVE) represents veterinary organisations from 38 European countries and includes four technical sections representing key groups in the veterinary profession (veterinary practitioners, veterinary public health, state veterinarians and veterinarians working for academies, industry and education. The European veterinary profession, embodied by FVE, strives to enhance animal health, animal welfare, public health and the protection of the environment by promoting the veterinary profession. Together with its members, FVE aims to support veterinarians in delivering their professional responsibilities to the best possible standard, and that this expertise is recognized and valued by society. FVE plays a vital part in making sure veterinarians can do their jobs well – for everyone’s benefit.

About MSD Animal Health

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (